Today: 3 May 2026
Browse Category

NYSE:LLY 23 December 2025 - 31 December 2025

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares edged up 0.1% after hours to $1,079.75 following news it and Novo Nordisk are cutting prices on top obesity drugs in China. Novo confirmed Wegovy price reductions; a hospital WeChat post showed Mounjaro’s 10mg pen dropping to 445 yuan ($63) from 2,180 yuan. Novo’s U.S. shares slipped about 0.5%. Lilly Endowment Inc. disclosed selling 3,593 shares in a regulatory filing.
30 December 2025
···
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly shares rose 0.2% to $1,078.73 in after-hours trading Monday, with 1.64 million shares traded. Lilly Endowment Inc. disclosed the sale of 2,629 shares at $1,085.17 each, retaining over 92 million shares. Investors focused on obesity drug pricing, with Lilly and Novo Nordisk preparing pill versions and shifting to telehealth and direct-to-consumer sales. The S&P 500 fell 0.35% and the Nasdaq lost 0.5%.
29 December 2025
··
Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly shares closed at $1,077.75, up $0.55, after ABL Bio announced it will receive $40 million upfront and a $15 million equity investment from Lilly under a research deal. The agreement follows a broader pact valued at up to $2.6 billion. Investors are watching for 2026 regulatory decisions on Lilly’s obesity drug pipeline. The S&P 500 and Dow slipped slightly on Friday.
29 December 2025
··
Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly shares closed at $1,077.75 Friday, near record highs, as U.S. markets shut for the weekend. ABL Bio announced $55 million in new funding tied to Lilly, including a $40 million upfront payment and $15 million equity investment. Investors remain focused on obesity-drug momentum and the FDA’s recent approval of Novo Nordisk’s weight-loss pill.
28 December 2025
·
Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly shares closed near record highs Friday at $1,077.75, with trading volume muted ahead of the weekend. ABL Bio announced it expects a $40 million upfront payment and $15 million equity investment from Lilly tied to their Grabody platform collaboration. The deal targets obesity and muscle diseases. Novo Nordisk’s oral Wegovy approval this week intensified competition in the obesity drug market.
28 December 2025
··
Eli Lilly Stock (LLY) Update: Latest Price, Fresh Headlines, Analyst Forecasts, and What to Watch Before Markets Reopen

Eli Lilly Stock (LLY) Update: Latest Price, Fresh Headlines, Analyst Forecasts, and What to Watch Before Markets Reopen

Eli Lilly shares ended Friday at $1,077.75, near record highs, as the market weighed strong demand for obesity drugs against rising pricing and access pressures. Novo Nordisk’s FDA approval for an oral Wegovy pill this week put pressure on Lilly, whose own oral therapy is expected in 2026. The stock’s equity value remains around $1 trillion. U.S. markets reopen Monday, with traders watching for weekend developments.
27 December 2025
·
Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly shares closed Friday near $1,077.75, little changed after a narrow session. The Centers for Medicare & Medicaid Services this week announced a plan to expand GLP‑1 drug access, capping monthly costs at $50 for Medicare beneficiaries. A Trump-era pricing deal also sets lower reference prices for weight-loss drugs. Investors are watching policy shifts as key drivers for LLY’s valuation.
27 December 2025
··
Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly shares traded near $1,075 Friday afternoon, down 0.2% in thin post-Christmas trading as U.S. indexes hovered close to record highs. The stock moved between $1,068 and $1,082 amid muted volume. The NYSE and Nasdaq remained open for a regular session. Investors continue to watch Lilly’s pricing moves and its lead in obesity and diabetes treatments.
26 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (NASDAQ: ABVX) rose about 5.3% to $145.31 in premarket trading Friday, with U.S. markets the main venue as Euronext remained closed for St. Stephen’s Day. The stock has surged in December amid Eli Lilly takeover rumors, recent inclusion in the Nasdaq Biotechnology Index, and ongoing interest in its ulcerative colitis drug obefazimod.
26 December 2025
···
Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open

Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open

Eli Lilly stock last traded at $1,076.98 before the holiday break, with after-hours pricing at $1,077.97. Trading resumes Friday amid new U.S. policy moves to expand GLP-1 drug coverage and push prices lower, including a CMS model and TrumpRx pricing plan. Investors are watching for price swings as thinner holiday-week liquidity meets headline risk.
26 December 2025
··
Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly shares closed at $1,076.98 after the early NYSE close on Dec. 24, with after-hours quotes near $1,077–$1,078 in thin holiday trading. U.S. exchanges remained shut Dec. 25 for Christmas. The 52-week range stands at $623.78 to $1,111.99. Trading volume is expected to rise when markets reopen Friday, with attention on GLP-1 policy and competition.
25 December 2025
·
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly shares closed up 0.50% at $1,076.98 in light Christmas Eve trading, then slipped to $1,071.74 after hours amid thin volume. The move followed news that U.S. regulators plan to expand Medicaid and Medicare coverage for GLP‑1 obesity drugs, including Lilly’s Zepbound, with a $50 monthly cap for Medicare starting January 2027.
24 December 2025
···
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly shares rose 0.47% to $1,076.67 in light Christmas Eve trading, with volume just over 200,000 shares by late morning. Investors focused on new GLP-1 headlines, including regulatory updates and global expansion, as well as a Reuters report showing Lilly’s Mounjaro outpacing Novo’s Wegovy in India since March. Indian generics are expected to intensify competition as patent expiries approach.
24 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly shares closed down 0.45% at $1,071.64 on Tuesday after the FDA approved Novo Nordisk’s Wegovy pill, the first oral GLP‑1 drug for chronic weight management in the U.S. Novo shares rose on the news, while Lilly stock traded flat in after-hours. Investors focused on the competitive impact of the new oral treatment on Lilly’s obesity franchise. Trading volume reached about 2 million shares.
23 December 2025
··
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly shares hovered near record highs Tuesday after the FDA approved Novo Nordisk’s first oral Wegovy pill, intensifying rivalry in the obesity drug market. LLY traded around $1,077 as investors weighed Novo’s launch against Lilly’s own oral candidate, orforglipron, which could reach the market in 2026. Both firms have signaled lower pricing for new pills as competition heats up.
23 December 2025
···
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly shares traded near $1,076 after the FDA approved Novo Nordisk’s first daily oral Wegovy for obesity. Novo plans a U.S. launch in January 2026, beating Lilly’s own oral candidate, which remains under review. Novo shares rose on the news; Lilly slipped slightly. Analysts expect oral obesity drugs could reach 20% of the market by 2030.
23 December 2025
··
1 … 5 6 7 8 9 … 12

Stock Market Today

  • Fidelity National Financial (FNF) Valuation Snapshot Amid Volatile Share Performance
    May 3, 2026, 4:41 AM EDT. Fidelity National Financial (NYSE:FNF) shares have shown volatile performance, with recent one-month gains around 13% contrasting a 6.4% decline over three months. Trading near $51.63, the stock is estimated to be 20% undervalued based on discounted cash flow analysis, indicating potential upside towards a $64.60 fair value. The company's expansion into fee-based segments and reinsurance aims to stabilize long-term earnings and reduce dependence on cyclical title revenues. However, a price-to-earnings ratio (P/E) of 23.3, higher than the industry's 11.5 average, signals a valuation premium that could bring risks if growth slows. Investors should weigh potential gains against risks such as continued real estate market weakness and rising expenses impacting earnings.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 03.05.2026

3 May 2026
Rivian shares fell 8.4% to $15.02 after first-quarter results beat expectations, as investors focused on cash burn and profitability concerns. Trading volume jumped 78% above average. The company plans to ramp up R2 SUV production in Georgia to 300,000 units annually. Tesla and Lucid Group shares both rose more than 2%.
Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

3 May 2026
Vertiv shares hit a 52-week high Friday before closing at $328.31, following a 30% jump in Q1 net sales to $2.65 billion. The company raised its 2026 outlook and recently acquired Strategic Thermal Labs, expanding its liquid cooling portfolio. Investors await further details at Vertiv’s May 19-20 conference in South Carolina.
AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

3 May 2026
AT&T closed a $6 billion sale of long-dated notes on April 30, with maturities ranging from 2033 to 2066, according to an SEC filing. The company reported first-quarter free cash flow of $2.5 billion, down from $3.1 billion a year earlier, citing higher capital investment. AT&T is preparing to close a $23 billion purchase of EchoStar spectrum licenses. CFO Pascal Desroches said net debt to adjusted EBITDA rose to 2.71 times.
Go toTop